Publications

2022

Xu D, Liu S, Wu X, Marti TM, Dorn P, Schmid RA, Peng RW, Shu Y. Dissecting the Immunological Profiles in NSD3-Amplified LUSC through Integrative Multi-Scale Analyses. Cancers (Basel). 2022 Oct 12;14(20):4997. PMID: 36291782.

Karatkevich D, Deng H, Gao Y, Flint E, Peng RW, Schmid RA, Dorn P, Marti TM. Schedule-Dependent Treatment Increases Chemotherapy Efficacy in Malignant Pleural Mesothelioma. Int J Mol Sci. 2022 Oct 8;23(19):11949. PMID: 36233258.

Gao Y, Kruithof-de Julio M, Peng RW, Dorn P. Organoids as a Model for Precision Medicine in Malignant Pleural Mesothelioma: Where Are We Today? Cancers (Basel). 2022 Aug 2;14(15):3758. PMID: 35954422.

Yang H, Yao F, Peng RW. Revisiting "BAP1ness" in Malignant Pleural Mesothelioma. J Thorac Oncol. 2022 Aug;17(8):e67-e69. PMID: 35931424.

Deng H, Gao Y, Trappetti V, Hertig D, Karatkevich D, Losmanova T, Urzi C, Ge H, Geest GA, Bruggmann R, Djonov V, Nuoffer JM, Vermathen P, Zamboni N, Riether C, Ochsenbein A, Peng RW, Kocher GJ, Schmid RA, Dorn P, Marti TM. Targeting lactate dehydrogenase B-dependent mitochondrial metabolism affects tumor initiating cells and inhibits tumorigenesis of non-small cell lung cancer by inducing mtDNA damage. Cell Mol Life Sci. 2022 Jul 25;79(8):445. PMID: 35877003.

Yang H, Sun B, Fan L, Ma W, Xu K, Hall SRR, Wang Z, Schmid RA, Peng RW, Marti TM, Gao W, Xu J, Yang W, Yao F. Multi-scale integrative analyses identify THBS2+ cancer-associated fibroblasts as a key orchestrator promoting aggressiveness in early-stage lung adenocarcinoma. Theranostics. 2022 Mar 28;12(7):3104-3130. PMID: 35547750.

Yang H, Berezowska S, Dorn P, Zens P, Chen P, Peng RW, Marti TM, Kocher GJ, Schmid RA, Hall SRR. Tumor-infiltrating lymphocytes are functionally inactivated by CD90+ stromal cells and reactivated by combined Ibrutinib and Rapamycin in human pleural mesothelioma. Theranostics. 2022 Jan 1;12(1):167-185. PMID: 34987640.

2021

Yang Z, Liang SQ, Saliakoura M, Yang H, Vassella E, Konstantinidou G, Tschan M, Hegedüs B, Zhao L, Gao Y, Xu D, Deng H, Marti TM, Kocher GJ, Wang W, Schmid RA, Peng RW. Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS-mutant cancer. EMBO Mol Med. 2021 Aug 8:e13193. doi: 10.15252/emmm.202013193. Epub ahead of print. PMID: 34369083.

Yang H, Sun B, Xu K, He Y, Zhang T, Hall SRR, Tan ST, Schmid RA, Peng RW, Hu G, Yao F. Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer. EBioMedicine. 2021 Jul;69:103457. doi: 10.1016/j.ebiom.2021.103457. Epub 2021 Jul 3. PMID: 34224975; PMCID: PMC8264109.

Ma L, Andrieu T, McKinnon B, Duempelmann L, Peng RW, Wotzkow C, Müller C, Mueller MD. Epithelial-to-mesenchymal transition contributes to the downregulation of progesterone receptor expression in endometriosis lesions. J Steroid Biochem Mol Biol. 2021 Jun 16;212:105943. doi: 10.1016/j.jsbmb.2021.105943. Epub ahead of print. PMID: 34144151.

Zhang T, Sun B, Zhong C, Xu K, Wang Z, Hofman P, Nagano T, Legras A, Breadner D, Ricciuti B, Divisi D, Schmid RA, Peng RW, Yang H, Yao F. Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma. Transl Lung Cancer Res. 2021 Apr;10(4):1857-1872. doi: 10.21037/tlcr-21-303. PMID: 34012798; PMCID: PMC8107764.

Gao Y, Zens P, Su M, Gemperli CA, Yang H, Deng H, Yang Z, Xu D, Hall SRR, Berezowska S, Dorn P, Peng RW, Schmid RA, Wang W, Marti TM. Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5'-deoxy-5-fluorocytidine (5'-DFCR). J Exp Clin Cancer Res. 2021 Apr 19;40(1):138. doi: 10.1186/s13046-021-01938-2. PMID: 33874986; PMCID: PMC8056724.

Xu D, Liang SQ, Yang Z, Yang H, Bruggmann R, Oberhaensli S, Berezowska S, Marti TM, Hall SRR, Dorn P, Kocher GJ, Schmid RA, Peng RW. Malignant pleural mesothelioma co-opts BCL-X_L and autophagy to escape apoptosis. Cell Death Dis. 2021 Apr 15;12(4):406. doi: 10.1038/s41419-021-03668-x. PMID: 33859162; PMCID: PMC8050302.

Yang H, Hall SRR, Sun B, Zhao L, Gao Y, Schmid RA, Tan ST, Peng RW, Yao F. NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma. Cancers (Basel). 2021 Mar 29;13(7):1561. doi: 10.3390/cancers13071561. PMID: 33805359; PMCID: PMC8036327.

Yang Z, Liang SQ, Yang H, Xu D, Bruggmann R, Gao Y, Deng H, Berezowska S, Hall SRR, Marti TM, Kocher GJ, Zhou Q, Schmid RA, Peng RW. CRISPR-Mediated Kinome Editing Prioritizes a Synergistic Combination Therapy for FGFR1-Amplified Lung Cancer. Cancer Res. 2021 Jun 1;81(11):3121-3133. doi: 10.1158/0008-5472.CAN-20-2276. Epub 2021 Mar 8. PMID: 33685992.

2020

Yang H, Xu D, Schmid RA, Peng RW. Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma. Ther Adv Med Oncol. 2020 Nov 12;12:1758835920971421. doi: 10.1177/1758835920971421. PMID: 33240401; PMCID: PMC7672749.

Yang H, Yao F, Marti TM, Schmid RA, Peng RW. Beyond DNA Repair: DNA-PKcs in Tumor Metastasis, Metabolism and Immunity. Cancers (Basel). 2020 Nov 16;12(11):3389. doi: 10.3390/cancers12113389. PMID: 33207636; PMCID: PMC7698146.

Yang H, Zhao L, Gao Y, Yao F, Marti TM, Schmid RA, Peng RW. Pharmacotranscriptomic Analysis Reveals Novel Drugs and Gene Networks Regulating Ferroptosis in Cancer. Cancers (Basel). 2020 Nov 5;12(11):3273. doi: 10.3390/cancers12113273. PMID: 33167414; PMCID: PMC7694346.

Rossi Sebastiano M, Pozzato C, Saliakoura M, Yang Z, Peng RW, Galiè M, Oberson K, Simon HU, Karamitopoulou E, Konstantinidou G. ACSL3-PAI-1 signaling axis mediates tumor-stroma cross-talk promoting pancreatic cancer progression. Sci Adv. 2020 Oct 30;6(44):eabb9200. doi: 10.1126/sciadv.abb9200. PMID: 33127675; PMCID: PMC7608806.

Xu D, Yang H, Schmid RA, Peng RW. Therapeutic Landscape of Malignant Pleural Mesothelioma: Collateral Vulnerabilities and Evolutionary Dependencies in the Spotlight. Front Oncol. 2020 Sep 23;10:579464. doi: 10.3389/fonc.2020.579464. PMID: 33072611; PMCID: PMC7538645.

Yang H, Xu D, Yang Z, Yao F, Zhao H, Schmid RA, Peng RW. Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma. Cancers (Basel). 2020 Aug 17;12(8):2310. doi: 10.3390/cancers12082310. PMID: 32824422; PMCID: PMC7465812.

Wang L, Dorn P, Simillion C, Froment L, Berezowska S, Tschanz SA, Haenni B, Blank F, Wotzkow C, Peng RW, Marti TM, Bode PK, Moehrlen U, Schmid RA, Hall SRR. EpCAM⁺CD73⁺ mark epithelial progenitor cells in postnatal human lung and are associated with pathogenesis of pulmonary disease including lung adenocarcinoma. Am J Physiol Lung Cell Mol Physiol. 2020 Nov 1;319(5):L794-L809. doi: 10.1152/ajplung.00279.2019. Epub 2020 Jul 29. PMID: 32726135.

Yang H, Xu D, Gao Y, Schmid RA, Peng RW. Oncolytic Viral Therapy for Malignant Pleural Mesothelioma. J Thorac Oncol. 2020 Jul;15(7):e111-e113. doi: 10.1016/j.jtho.2020.03.007. PMID: 32593447.

Yang H, Xu D, Gao Y, Schmid RA, Peng RW. The Association of BAP1 Loss-of-Function With the Defect in Homologous Recombination Repair and Sensitivity to PARP-Targeted Therapy. J Thorac Oncol. 2020 Jun;15(6):e88-e90. doi: 10.1016/j.jtho.2020.02.028. PMID: 32471567.

Wang L, Dorn P, Zeinali S, Froment L, Berezowska S, Kocher GJ, Alves MP, Brügger M, Esteves BIO, Blank F, Wotzkow C, Steiner S, Amacker M, Peng RW, Marti TM, Guenat OT, Bode PK, Moehrlen U, Schmid RA, Hall SRR. CD90⁺CD146⁺ identifies a pulmonary mesenchymal cell subtype with both immune modulatory and perivascular-like function in postnatal human lung. Am J Physiol Lung Cell Mol Physiol. 2020 Apr 1;318(4):L813-L830. doi: 10.1152/ajplung.00146.2019. Epub 2020 Feb 19. PMID: 32073879.

Gao Y, Dorn P, Liu S, Deng H, Hall SRR, Peng RW, Schmid RA, Marti TM. Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment. Cancer Cell Int. 2019 Nov 29;19:317. doi: 10.1186/s12935-019-1037-1. PMID: 31798346; PMCID: PMC6883680.

Xu D, Liang SQ, Yang H, Bruggmann R, Berezowska S, Yang Z, Marti TM, Hall SRR, Gao Y, Kocher GJ, Schmid RA, Peng RW. CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma. Mol Cancer Ther. 2020 Feb;19(2):661-672. doi: 10.1158/1535-7163.MCT-19-0724. Epub 2019 Nov 6. PMID: 31694888.

Mohsenzadegan M, Peng RW, Roudi R. Dendritic cell/cytokine-induced killer cell-based immunotherapy in lung cancer: What we know and future landscape. J Cell Physiol. 2020 Jan;235(1):74-86. doi: 10.1002/jcp.28977. Epub 2019 Jun 21. PMID: 31222740.

2019

Yang H, Liang SQ, Schmid RA, Peng RW. New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness. Front Oncol. 2019 Sep 25;9:953. doi: 10.3389/fonc.2019.00953. PMID: 31612108; PMCID: PMC6773824.

Xu D, Yang H, Yang Z, Berezowska S, Gao Y, Liang SQ, Marti TM, Hall SRR, Dorn P, Kocher GJ, Schmid RA, Peng RW. Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma. Cancers (Basel). 2019 Oct 8;11(10):1502. doi: 10.3390/cancers11101502. PMID: 31597321; PMCID: PMC6827154.

Yang H, Liang SQ, Xu D, Yang Z, Marti TM, Gao Y, Kocher GJ, Zhao H, Schmid RA, Peng RW. HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer. Oncogenesis. 2019 Aug 20;8(9):45. doi: 10.1038/s41389-019-0158-7. PMID: 31431614; PMCID: PMC6702198.